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Summary
PTPA, an essential and specific activator of protein
phosphatase 2A (PP2A), functions as a peptidyl prolyl
isomerase (PPIase). We present here the crystal struc-
tures of human PTPA and of the two yeast orthologs
(Ypa1 and Ypa2), revealing an all a-helical protein
fold that is radically different from other PPIases. The
protein is organized into two domains separated by
agroove linedbyhighly conserved residues. Tounder-
stand themolecularmechanismof PTPA activity, Ypa1
was cocrystallized with a proline-containing PPIase
peptide substrate. In the complex, the peptide binds
at the interface of a peptide-induced dimer interface.
Conserved residuesof the interdomaingroovecontrib-
ute to the peptide binding site and dimer interface.
Structure-guided mutational studies showed that in
vivo PTPA activity is influenced by mutations on the
surface of the peptide binding pocket, the same muta-
tions that also influenced the in vitro activation of
PP2Ai and PPIase activity.
Introduction
PP2A is one of the major protein serine/threonine phos-
phatases responsible for regulating the levels of intra-
cellular protein phosphorylation (Janssens and Goris,
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verse activities, including metabolism, DNA replication,
transcription, RNA splicing, translation, cell cycle pro-
gression, morphogenesis, development, and transfor-
mation. Its capacity to regulate these processes is
governed by regulatory and targeting subunits and
posttranslational modification.
The core PP2A holoenzyme comprises a 36 kDa cata-
lytic subunit (PP2AC) and a 65 kDa HEAT-motif contain-
ing scaffolding subunit (PR65/A) (Groves et al., 1999).
This core heterodimer (PP2AD) either exists indepen-
dently (Kremmer et al., 1997) or associates with one of
a variety of variable (B) subunits, which confer regula-
tory and specificity functions (Janssens and Goris,
2001). The three major classes of B subunit (PR55/B,
PR61/B0, and PR72/B0 0) share little sequence similarity,
except for two conserved A subunit binding domains
(Li and Virshup, 2002). Mechanisms that regulate PP2A
include variation in its subunit composition (reviewed
in Janssens et al. [2005]), inactivating threonine and ty-
rosine phosphorylations of its catalytic subunit (Chen
et al., 1992; Guo and Damuni, 1993), phosphorylation
of PR61/B0 subunits (McCright et al., 1996; Usui et al.,
1998), and reversible methylation (Favre et al., 1994) of
the PP2AC C terminus catalyzed by the specific methyl-
transferase LCMT (PP2A leucine carboxyl methyltrans-
ferase) (De Baere et al., 1999; Leulliot et al., 2004) and
methylesterase PME-1 (Ogris et al., 1999).
PP2A is also regulated by the action of PTPA, a protein
that was originally described for its capacity to stimulate
the tyrosyl phosphatase activity of PP2AD (Cayla et al.,
1990). However, recent findings suggest that its physio-
logical function is more likely to reactivate the Ser/Thr
phosphatase activity of an inactive form of PP2A
(PP2Ai) (Longin et al., 2004; Van Hoof et al., 2005; Jor-
dens et al., 2006) that forms a stable complex with
PME-1 (Longin et al., 2004). Human PTPA is encoded
by a single gene, mapped to chromosome 9q34 (Van
Hoof et al., 1995). The transcription gives rise to seven
different splice variants, four of which are active (Jans-
sens et al., 2000b). Basal expression of the gene is
dependent on the ubiquitous transcription factor Yin
Yang 1 (Janssens et al., 1999) and functionally antago-
nized by p53 (Janssens et al., 2000a).
In budding yeast, PTPA is encoded by two genes,
YPA1 and YPA2 (also named RRD1 and RRD2 for Rapa-
mycin-resistant deletion). Individual deletion of YPA1
produces a more severe phenotype than deletion of
YPA2. Deletion of YPA1 leads to an aberrant bud mor-
phology, abnormal actin distribution, growth defects,
and rapamycin resistance (Van Hoof et al., 2000, 2001;
Rempola et al., 2000). Ypa1 and Ypa2 deletions confer
rapamycin resistance probably by indirect regulation of
TOR, the key component of a nutrient sensing signaling
cascade that controls a wide spectrum of growth-
related events in response to nutrient availability and
growth factor signaling (see Jacinto and Hall [2003] and
Zabrocki et al. [2002] for reviews). Whereas Ypa1 has a
major role in the G1 phase of the cell cycle (Van Hoof
et al., 2000) and also functions in the regulation of the
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414G2/M transition (Mitchell and Sprague, 2001), Ypa2 func-
tions in M phase (Van Hoof et al., 2001). Deletion of both
genes is lethal (Van Hoof et al., 2000, 2001; Rempola
et al., 2000), although this synthetic lethality is sup-
pressed by the ‘‘viable’’ allele (SSD1-v1) of the SSD1
(suppressor of Sit4 defects) gene (Rempola et al., 2000;
Fellner et al., 2003; Kaeberlein et al.,2004), suggesting
that Ypa1 and Ypa2 might function in the cell integrity
pathway. Loss of PTPA function caused the synthesis
of a less stable form of PP2A with an increased protein
tyrosine phosphatase-like activity, as assessed by its
capacity to dephosphorylate the phosphotyrosine
mimetic p-nitrophenol phosphate (Fellner et al., 2003).
This suggested that PTPA was probably essential for de-
fining the native conformation of PP2A (Fellner et al.,
2003). Genetic evidence identified YPA1 and YPA2 as
positive regulators of PP2A (Rempola et al., 2000; Van
Hoof et al., 2000) and PP2A-related phosphatases
such as Sit4 (Mitchell and Sprague, 2001, Douville
et al.,2004), implicated in the regulation of the TOR path-
way (Van Hoof et al., 2005). Recent studies revealed that
Ypa1 physically interacts with the PP2A-like phospha-
tases Pph3, Sit4, and Ppg, whereas Ypa2 binds to
Pph21 and Pph22, the yeast homologs of PP2A. This lat-
ter interaction is promoted by Ypa1 (Van Hoof et al.,
2005). Moreover, the different PP2A-like phosphatases
in yeast (Pph21, Pph22, Pph3, Sit4, and Ppg) can exist
as inactive conformers that can be activated by Ypa1
or Ypa2 (Van Hoof et al., 2005).
The activation of PP2A by PTPA, Ypa1, or Ypa2 is de-
pendent on ATP or a hydrolysable ATP analog with Mg2+
(Cayla et al., 1990; Van Hoof et al., 1998). However, a ki-
nase activity could not be demonstrated, consistent
with the absence of detectable kinase sequence signa-
ture motifs. The mechanism of activation remained elu-
sive until the recent identification of PTPA/Ypa1/Ypa2 as
a peptidyl-prolyl cis/trans isomerase (PPIase) (Jordens
et al., 2006). Moreover, we were able to propose the con-
served Pro190 in PP2AC as the target for an isomeriza-
tion reaction. This Pro190 is not only conserved during
evolution in the different species, but also the sequence
of the loop structure is also conserved in all PP2A-like
phosphatases, suggesting that the activation might be
a very specific mechanism.
In addition to their role in PP2A activation, stable ter-
nary complexes of Tap42-Ypa1-Sit4 and Tap42-Ypa2-
PP2AC have been observed (Van Hoof et al., 2005;
Zheng and Jiang, 2005). Yeast Tap42 and the mamma-
lian equivalent a4 are proteins that interact directly
with PP2AC independent of the PR65/A subunit and
are known to be important players in the TOR signaling
pathway (Di Como and Arndt, 1996; Murata et al., 1997)
(see Jacinto and Hall [2003] for a review). The human ho-
molog of Tap42, a4, is also described as an inhibitor of
apoptosis (Kong et al., 2004). A partially overlapping
role for Ypa1 and Tap42-associated PP2A or PP2A-like
phosphatases is suggested from the finding that over-
expression of Tap42 suppresses the rapamycin resis-
tance of the Ypa1 deletion strain (Van Hoof et al.,
2005). However, the mechanisms by which Tap42/Ypa/
PP2A complexes interfere with the TOR signaling path-
way are still largely unknown.
In an effort to understand the mechanism of PTPA ac-
tion at the molecular level, we determined the crystalstructures of both yeast Ypa1 and Ypa2 as well as human
PTPA. The three structures are very similar, revealing an
alla-helical protein fold where highly conserved residues
line a groove between two lobes of the molecule. In order
to understand the basis of PTPA action, we cocrystal-
lized Ypa1 with a peptide active in the prolyl-isomerase
reaction. The complex provides a definition of the pep-
tide binding site and reveals that a group of conserved
residues were involved in dimerization of the protein.
Structure-guided mutational studies showed that in
vivo PTPA activity is influenced by mutations on the sur-
face of the peptide binding pocket, the same amino acids
that also influenced the in vitro activation of PP2Ai and
PPIase activity.
Results
Structure Determination
Because full-length Ypa1, Ypa2, and hPTPA (isoform a)
proteins failed to crystallize, we decided to construct
truncated versions of these proteins by removing non-
structured regions identified by sequence analysis and
limited proteolysis. These regions correspond to the
C-terminal region of Ypa1 and Ypa2 and the N-terminal
region of hPTPA (Figure 1). The crystallized proteins,
named Ypa1D, Ypa2D, and hPTPAD hereafter, comprise
regions 1–320, 1–304, and 20–323, respectively. The
structure of Ypa2D was solved by single anomalous dif-
fraction using selenomethionine-substituted crystals.
The radiation damage on the selenium atoms was mod-
eled and used in a ‘‘continuous’’ radiation damage-in-
duced phasing (RIP) scheme implemented in SHARP
in order to obtain interpretable electron density maps
(see Experimental Procedures) (Schiltz et al., 2004).
The resulting maps enabled the two protein chains pres-
ent in the asymmetric unit to be modeled. The structure
of Ypa1D was solved by molecular replacement using a
model derived from the Ypa2D structure. Application of
density modification reflecting the 2-fold symmetry of
the two monomers present in the asymmetric unit was
necessary to yield a high-quality map. Despite the pres-
ence of noncrystallographic translational symmetry and
severe anisotropy of the diffraction data, the structure of
Ypa1D in complex with the peptide substrate was solved
by molecular replacement using the native Ypa1D struc-
ture as a search model. Four copies of Ypa1Dare present
in the asymmetric unit. In contrast to the monomeric as-
sembly of Ypa1D in the absence of peptide, the protein
formed two independent dimers in the asymmetric unit
when in complex with the peptide substrate (see below).
The structure of hPTPAD was solved independently by
single anomalous diffraction (SAD) using selenomethio-
nine-derived crystals. hPTPAD data collection did not
undergo radiation damage, and initial SAD-derived
phases resulted in a readily interpretable high-resolution
electron density map. There is one hPTPADmolecule per
asymmetric unit, and the structure was refined to 1.5 A˚
resolution. Data collection and refinement statistics are
reported in Table 1.
PTPA Represents an All Helical PPIase Architecture
The Ypa1D, Ypa2D, and hPTPAD proteins share on aver-
age 38% sequence identity and therefore possess an
identical fold, belonging to the all a class (topology in
Crystal Structure of PP2A Phosphatase Activator
415Figure 1. Multiple Sequence Alignment of PTPA Proteins
Alignment was performed with CLUSTAL W (Thompson et al., 1994) and represented with ESPRIPT (Gouet et al., 1999). The proteins have been
separated in three families: Ypa1-like (S. cerevisiae, S. pombe,C. albicans, andG. zeae), hPTPA-like (A. thaliana,M.musculus,O. cuniculus, and
H. sapiens), and Ypa2-like (S. cerevisiae,S. pombe,C. albicans, andG. zeae). Secondary structure elements as extracted from the present crystal
structures are superposed. The amino acids deleted in the inactive mutant of O. cuniculus are indicated by black triangles. The absolutely
conserved tryptophan involved in stacking with the proline ring is highlighted in green.Figure 2A). The PTPA fold is composed of 14 a helices,
organized into two discrete domains each of w25 A˚ in
diameter. The interface of the two domains defines
a prominent groove. Helices a3–a7 (shades of blue in
Figure 2A) stack by extensive hydrophobic interactions
and form a well-defined five helical bundle. This helical
bundle defines a structural domain of the PTPA fold (do-
main A) and displays superficial similarity to the cyclin
box fold. However, both the topology and relative dispo-
sition of the five antiparallel helices of domain A of PTPA
differ from the cyclin box structure (Figure 3). Moreover,
the narrow conserved groove at the domain interface
is analogous to the peptide binding groove within the
N-terminal cyclin box folds of cyclin A (Brown et al.,
1999) and retinoblastoma (Lee et al., 1998). The second
domain (domain B, shades of red and purple in Fig-
ure 2A) contains helices a8–a13, with a8 and a11 pack-
ing along sides a6 and a7 of domain A. Domain B shares
a similar topology to domain A, although in contrast to
domain A where the average length of the helices is six
to seven turns, the a helices of domain B comprise
only two to three turns. The N-terminal helices a1 and
a2 (shades of green in Figure 2) run along the lengths
of both domains A and B, whereas the C-terminal helix
a14 stacks on the a1 helix.
The overall structures of Ypa1D, Ypa2D, and hPTPAD
are essentially identical with an average root-mean-
square deviation (rmsd) of 1.1 A˚ (Figure 2B). All a helices
are perfectly superimposable in the three proteins, andthe largest differences between the three homologs are
confined to conformational changes of the a2-a3 and
a8-a9 loops. For some copies in the asymmetric units
of Ypa1D and Ypa2D, a few residues of the a3-a4 and
a7-a8 loops are not visible in the electron density, sug-
gesting that these loops are flexible. A search for struc-
tural homologs with full-length or with separate domains
of PTPA did not retrieve significant matches. The Ypa1D,
Ypa2D, and hPTPAD structures therefore did not initially
provide clear insights into their biochemical function.
Sequence alignment of PTPA homologs shows that they
contain an almost absolutely conserved a7-a8 loop (Fig-
ure 1). This loop connects domain A and B and lines the
groove at the interface of the two domains (Figures 2C
and 2D, see also Figure S4 available in the Supplemental
Data with this article online). The other residues lining
this groove are also mostly conserved and belong to
the a3-a4, a5-a6, and a11-a12 loops and to a13 helix
(Figure 2C and Figure S4). This highly conserved groove,
confined between the two domains, would seem to be an
ideal candidate for harboring the biochemical function of
PTPA proteins. However, no canonical ligand binding,
metal binding, or putative catalytic site could be identi-
fied in this groove.
Prolyl Containing Peptides Bind to a Conserved
Region at a Peptide-Induced Dimer Interface
The biochemical function of PTPA proteins was recently
identified as a peptidyl-proline isomerase activity by the
Molecular Cell
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Protein hPTPA (Native) Yap2D (SeMet pk) Yap1D Yap1D+ppi-Peptide
Space group P212121 C2221 P212121 P65
Unit-cell parameters: a, b, c (A˚) 48.2 70.4 95.5 157.9 171.0 53.7 53.1 94.2 139.8 86.9 86.9 410.6
Resolution (A˚) 1.50 (1.58–1.50) 2.8 (2.87–2.8) 2.6 (2.74–2.6) 2.8 (2.95–2.80)
Total number of reflections 311,889 (44,972) 176,445 (13,572) 133,991 (18,579) 165,026 (24,003)
Total of unique reflections 52,866 (7599) 19,075 (1938) 21,334 (3181) 42,938 (6228)
Multiplicity 5.9 (5.0) 9.3 (7.1) 6.3 (5.8) 3.8 (3.8)
Rmerge
a 0.091 (0.296) 0.192 (0.55) 0.139 (0.429) 0.198 (0.647)
I/s(I) 13.7 (5.9) 11.5 (2.6) 11.9 (3.7) 5.7 (2.0)
Overall completeness (%) 99.9 (100) 91.4 (95.2) 95.5 (100.0) 99.9 (99.9)
R/Rfree (%)
b 20.2/22.1 20.2/27.3 21.4/29.0 21.6/29.2
Rmsd bonds (A˚) 0.009 0.022 0.018 0.024
Rmsd angles () 1.21 2.26 1.84 2.48
Ramachandran plot (%)
Most favored 93.6 85.7 90.5 82.4
Allowed 6.4 14.3 9.5 17.6
a Rmerge = ShSi j Ihi 2 <Ih>j /ShSiIhi, where Ihi is the ith observation of the reflection h, whereas <Ih> is the mean intensity of reflection h.
b Rfactor =SkFoj 2 jFck / jFoj. Rfree was calculated with a small fraction (5%) of randomly selected reflections.use of NMR spectroscopic and biochemical assays (Jor-
dens et al., 2006). Conventional peptidyl-proline isomer-
ases belong to three distinct families (cyclophilins,
FKBPs, and parvulins) whose structure and mechanism
have been extensively studied. Their folds are all char-
acterized by a central b sheet. Clearly, PTPA is structur-
ally unrelated to any of these PPIases. Therefore, in or-
der to elucidate the structural basis of PPIase activity
of PTPA proteins, we performed cocrystallization trials
with all the PTPA homologs using different peptide
mimics. These short peptides (four to ten residues),
synthesized with PP2AC sequences centered on proline
residues, had previously been tested in the PPIase
reaction.
Of all the different trials performed, using all three
PTPA homologs, only cocrystallization of Ypa1D with
LQEVPHEGPMCDL, the PP2A peptide active in PPIase
reaction, and succinyl-AlaAlaProLys-paranitroanilide
(suc-AAPK-pNa), the standard substrate used in the bio-
chemical activity assay for PPIases, were successful (in
the same crystallization conditions). Only crystals with
suc-AAPK-pNa gave sufficient diffraction to solve the
structure. The structure of the complex was solved by
molecular replacement using the native Ypa1 structure
as a model and unexpectedly revealed two dimers in
the asymmetric unit. The dimerization mode of Ypa1D
is a head-to-head dimer with proper 2-fold symmetry
(Figures 4A and 4B).
Dimer formation is achieved by interactions of the a7-
a8 and a3-a4 loops onto the opposing a7-a8 and a3-a4
loops, respectively, and of the a5-a6 loop onto the a11-
a12 loop. Dimerization involves w24 residues and bur-
ies 1100 A˚2 of accessible surface mainly by hydrophobic
interactions. Two hydrogen bonds (Ser198-Val201) and
four salt bridges (Glu265-Arg141 and Glu194-Arg92)
are formed across the complex interface. Structural re-
arrangements are mainly localized to the central a7-a8
loop, which in the native Ypa1D is partially unstructured.
Analytical ultracentrifugation demonstrates the pres-
ence of a monomer/dimer equilibrium in solution, but
quantification of these experiments is hampered by pre-
cipitation of the protein in the monomeric state. Prelim-inary ultracentrifugation experiments of sedimentation
equilibrium revealed aggregation of native Ypa1 and
Ypa1D in the first hours and the propensity of the ligand
succinate-AAPKpNA to slow down this aggregation
(data not shown). Apparent sedimentation coefficients
were calculated from early profiles of sedimentation ve-
locity experiments at one concentration with and with-
out ligand for both native Ypa1 and Ypa1D (Figure S1);
s values were not extrapolated at zero protein concen-
tration. Despite high residuals and broad c(s) peaks
protein aggregation, we found for both proteins species
s values compatible with monomers in the absence of
ligand, and monomers and dimers in the presence of
ligand.
At the outset of the crystallographic refinement, clear
unassigned electron density was visible in two pockets
of the Ypa1D dimer for both copies in the asymmetric
unit. This density could be unambiguously modeled
by the suc-AAPK-pNa peptide (Figure 4A). Apart from
the succinate residue, the entire peptide, including the
pNa chromophore, is well defined in the structure. The
presence of the chromophore and the lysine residue
clearly defines the direction of the peptide chain in the
electron density.
Two copies of the suc-AAPK-pNa peptide are bound
in two symmetrical pockets created at the Ypa1-dimer
interface. This pocket is lined with residues belonging
to a12, a13, and the a7-a8 loop from one monomer,
and a1, the N terminus of a14, from the other monomer
(Figure 4B). The peptide binds by extensive hydropho-
bic interactions (Figure S2). One hydrogen bond is
formed by the backbone oxygen of the second alanine
of the peptide and the backbone nitrogen of Phe299.
The absolutely conserved Lys298, which makes a salt
bridge to Glu294 in the same protein chain, is located
on average 4 A˚ from the succinate group, probably lead-
ing to favorable electrostatic interactions. Asp272
makes a salt bridge with the lysine present in the pep-
tide, but this aspartate is replaced by asparagine in
some organisms (Figure 1). Catalytic PPIase assays us-
ing NMR performed with peptide substrates that do not
contain a charged residue after the Pro show that this
Crystal Structure of PP2A Phosphatase Activator
417Figure 2. Structure of PTPA Homologs
(A) Topology of the PTPA fold. The bimodular structure is formed by domain A (helices 3–7) and domain B (helices 8–13).
(B) Structural superposition of hPTPAD (blue), Ypa1D (green), and Ypa2D (red), in about the same orientation as (C).
(C) Stereo cartoon representation of the Ypa1D monomer. The helices are colored with the same color code as (A).
(D) Surface representation of the Ypa1D monomer. The surface is color coded in increasing shades of red representing conservation of the
surface residue. The left panel has the same orientation as (C), whereas in the right panel, the Ypa1D monomer is rotated over 180.salt bridge is not required for PPIase activity (Jordens
et al., 2006). The most prominent feature of the
interaction is the hydrophobic sandwich interaction of
the suc-AAPK-pNa peptide proline with the side chains
of the absolutely conserved Trp202 and a minor contact
to Pro268 (Asn268 in group 2 PTPAs, see Figure 1).
Trp202 is itself stacked onto His199 of the opposing
monomer. The peptide is bound in a trans conformation
with Phi/Psi angles of 260/150 (Figure 4C).Conserved Residues Are Required for PP2A
Activating and PPIase Activity of Ypa1 Mutants
In previous investigations, we showed that the con-
served region 200GVWGLD205 of PTPA (Ypa1 numbering)
is essential for both the activation of the tyrosyl phos-
phatase activity of PP2AD as well as for the activation
of PP2Ai and the PPIase activity (Jordens et al., 2006;
Van Hoof et al., 1998). Deletion of this region diminished
PTPA activity. This absolutely conserved region,
Molecular Cell
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the protein, corresponds to the peptide binding site
(residue numbers highlighted in red in Figure 4B). The
structure of this mutant from O. cuniculus was probed
by CD spectroscopy to ensure that its loss of activity
was only due to the deleted binding site and not to
disruption of the overall structure. The CD spectra of
O. cuniculus PTPAD(200GVWGLD205) indicated no loss
of a-helical structure compared to wild-type PTPA of
the same species (Figure S3) or to wild-type Ypa1D
(data not shown).
We further explored the importance of individual
amino acids in this sequence by testing the PP2Ai
activation and PPIase activities of the following point
mutations: Trp202Gly, Gly203Phe, Asp205Gly, and
Asp206Gly (Table 2). The Asp205Gly mutation caused
similar changes in both PP2A activating and PPIase ac-
tivity as compared to the 200GVWGLD205 deletion mutant
(Jordens et al. [2006] and Table 2). The Asp206Gly mu-
tant is almost completely inactive in the activation and
50% less active in the PPIase reaction. The Trp202Gly
mutant and to a lesser extent Gly203Phe show a low spe-
cific activity in the activation reaction, although they
were active in the protease-based PPIase assay. Be-
cause the Trp202Gly mutant was expected to be inactive
as a PPIase, we sought independent evidence for the
PPIase activity of some mutants by dynamic protein
NMR spectroscopy using the band-shape analysis tech-
nique (Hu¨bner et al.,1991) as applied in Jordens et al.
(2006), with the Pro190-containing, PP2AC-derived pep-
tide 186LQEVPHEGPMCDL198 as substrate. By using this
method and substrate, the Trp202Gly mutant was inac-
tive as a PPIase, as was the Asp205Gly mutant (Figure 5,
compare with wild-type). A possible reason for this ap-
parent discrepancy between both methods is explained
in the Discussion.
We further tested the effect of mutations introduced
in most of the amino acids lining the groove between
domains A and B in the dimer interface region (Arg92,
Figure 3. Comparison of PTPA A Domain and the Cyclin A/Retino-
blastoma Fold
Comparison of the helical fold of domain A of PTPA with the cyclin
box fold of cyclin A. Both domains feature an antiparallel five a-he-
lical bundle, although the topology of the two domains differs.Lys259, and His266) (see Figure S4). As a control, we
tested mutants of residues that are part of a conserved
surface patch distinct from the peptide binding site and
dimerization interface (Arg185 and Phe254). Although
not as drastic as the Trp202, Asp205, or Asp206 point
mutants, the interface mutations at residues Arg92,
Lys259, and His266 slightly impair the capability of
PTPA/Ypa1 to activate PP2Ai, whereas the other mu-
tants (Arg185 and Phe254) hardly influenced the specific
activity as activator. None of the mutants significantly
influenced the PPIase activity, except for Asp205 and
Asp206, which diminished activity substantially. These
last mutants certainly hinder the peptide binding by
disrupting the protein dimer interface.
As a positive control, Leu270Ala and Val277Ala mu-
tants, located near the peptide groove without being
directly involved in binding, were designed to test for de-
stabilizing the overall structure of PTPA. The Val277Ala
was found to be about 5-fold less active as an activator
of PP2Ai in comparison with wild-type Ypa1, whereas
we found only a very low expression of soluble
Leu270Ala mutant and could therefore neither measure
activity changes nor PPIase activity.
Mutations of the Dimer Interface and Peptide
Binding Pocket Disrupt In Vivo Activity
We designed an assay for the effects of the mutations of
Ypa1 on a known physiologic effect of Ypa1 in vivo. De-
letion of Ypa1 in W303-1Aa yeast strains confers rapa-
mycin resistance (Van Hoof et al., 2000; Rempola et al.,
2000). Reintroduction of wild-type Ypa1 rescues this
phenotype. We reasoned that by reintroduction of a
nonfunctional Ypa1, the strains would still grow on rapa-
mycin. This was indeed the case for the Asp205Gly,
Asp206Gly, Leu270Ala, and Val277Ala mutants and
somewhat less for the Trp202Gly, Gly203Phe, and
Lys259Gly mutants, whereas none of the other Ypa1 de-
letion strains transfected with mutant Ypa1 showed any
growth after 5 days of incubation (the control Arg185Gly
mutant is shown as an example) (Table 2 and Figure S6).
Discussion
The activity of PP2A is subject to complex regulation.
The biochemical mode of action is well documented
for a few of its regulators (methyltransferase [De Baere
et al., 1999] and methyl esterase [Favre et al., 1994]),
whereas for others the activation mechanism remains
more elusive. PTPA is an activator of the inactive form
of PP2A, whose biochemical function was unknown until
recently. The activation of PP2Ai by PTPA, Ypa1, or Ypa2
is dependent on the presence of MgATP or a hydrolys-
able ATP analog. Surprisingly, PTPA does not possess
kinase activity, but ATP/Mg2+ stimulates the recently
discovered prolyl cis/trans isomerase activity of PTPA.
PTPA PPIase activity could be clearly demonstrated
with a biochemical assay that uses a generic peptide
and was comparable to activities from well-character-
ized PPIases such as cyclophilin and FKBP (Jordens
et al., 2006). Among the 14 proline residues of PP2A rep-
resented in synthetic peptides, only one reacted in the
presence of PTPA and ATP/Mg2+. Through the present
crystal structures of PTPA, Ypa1, and Ypa2, the molec-
ular basis of their action can be defined further.
Crystal Structure of PP2A Phosphatase Activator
419Figure 4. Structure of Ypa1D in Complex with the PPIase Substrate suc-AAPK-pNa
(A) Binding of the suc-AAPK-pNa peptide involves dimerization of Ypa1D. One monomer has the same color code as Figures 2A and 2B, the other
is represented in surface colored as in Figure 2D. The Fo 2 Fc electron density contoured at 3s is shown for the PPIase peptides.
(B) Stereo view of the peptide binding pocket. The two monomers are colored red and blue. The residues of the protein in proximity to the peptide
are labeled. The residues labeled in red correspond to the region deleted in the inactive mutant from O. cuniculus.
(C) Close-up view of the stacking interaction of Trp202 and the peptide proline. Peptide residues are labeled in bold.PTPA Proteins Define a Fold
PTPA, Ypa1, and Ypa2 are all bilobal proteins, contain-
ing exclusively a helices. Therefore, the apo protein
structures alone provided relatively few insights into
their mechanisms by comparison to known protein
structures. The majority of conserved surface residues
cluster into a groove situated between the two lobes
lined by well-conserved charged residues (Figure 2D).The structure of a complex between Ypa1 and the pep-
tide used for the biochemical isomerase assay yielded
crucial information to define the molecular mechanism
of PTPA. First, it showed that peptide binding induces
dimer formation, and second, it showed that the peptide
binds into a hydrophobic groove, juxtaposed to the di-
mer interface but devoid of a clear set of possible cata-
lytic residues. Analysis of the dimer interface against
Molecular Cell
420Table 2. Activity of Ypa1 Mutants In Vitro and In Vivo
Position Activator U/mg PPIase kobs s
21 3 1022 PPIAse NMR Based Growth on Rapamycin
Wt 200 6 10 7 6 1 Yes 2
Peptide binding interface
W202G a7-a8 31 6 8* 6 6 1 No ++
G203F a7-a8 120 6 20* 7.5 6 0.8 No +
P268A a12 210 6 10 NM Yes 2
Dimer interface
R 92G a3-a4 160 6 40 7.2 6 0.9 2 2
D205G a7-a8 4.9 6 0.8* 2.1 6 0.3* No +++
D206G a7-a8 40 6 1* 3.4 6 0.6* 2 +++
K259G a11 160 6 20 6.8 6 0.4 2 +
H266G a11-a12 150 6 10 7.4 6 0.7 2 2
Other conserved surface patch
R185G a7 200 6 80 6.5 6 0.6 2 2
F254G a11 190 6 20 7 6 1 2 2
Structure destabilizing
L270A a12 NM NM 2 ++
V277A a12-a13 40 6 2* 1.9 6 .1* 2 +++
Activity of the different Ypa1 mutants was measured by activating PP2Ai. PPIase activity of the different Ypa1 mutants was measured with the
protease-assisted method and suc-AAPK-pNA as substrate or with the 1H-NMR-based method and the PP2A-derived peptide. Details of the
different methods can be found in the Supplemental Data. All quantitative experiments were measured in triplicate. The mean values are given6
standard deviation. The significance of the difference (p value < 0.05) between the mutants and wild-type Ypa1 measurements is indicated by an
asterisk (*). NM means not measured. A minus sign (2) in the ‘‘PPIase NMR Based’’ column also means not measured.sequence data shows that dimer formation involves
highly conserved surface regions.
Ypa1 and Ypa2 physically interact with different phos-
phatases in vitro. Based on sequence conservation, it is
possible to group the PTPA proteins into three subfam-
ilies: PTPAs from higher eukaryotes and from the two
paralogous subfamilies in yeast (Figure 1). We presently
solved the structures of one member of each subfamily
and demonstrated structural conservation at the puta-
tive catalytic site. The variable residues defining the
three families are therefore probably involved in fine
tuning of the binding specificity of the PTPA protein to
PP2Ac and other PP2A-like phosphatases, and possibly
to the other PP2A regulatory subunits (Tpd3 and Tap42
in yeast).
PTPA Is a Peptidyl-Proline cis/trans Isomerase
with an Unknown Catalytic Mechanism
The PTPA fold is radically different from that of the con-
ventional prolyl cis/trans isomerases. Currently known
peptidyl-proline isomerases belong to three families:cyclophilins, FKBPs, and parvulins. The catalytic mech-
anism of these PPIases is still unclear, despite the wealth
of structural data relating to the three different PPIase
families and of their complexes with inhibitors, peptides,
or proteins (for review see Fanghanel and Fischer
[2004]). It also remains unclear if the catalytic pathway
of the enzymes of the three families is related or if they
adopt different strategies for their enzymatic activity.
A number of catalytic mechanisms have been pro-
posed for cis/trans isomerases, but the possibility of
a nucleophilic attack from a side chain in the PPIase ac-
tive site has been excluded. The acceleration of the cis/
trans isomerization of prolyl bonds involves the reduc-
tion of the double bond character of the C-N bond,
and hydrogen bonding of a catalytic site arginine to
the amide oxygen immediately C-terminal to the prolyl
residue also seems to play a role. PPIases bind and sta-
bilize a transition state that is characterized by partial ro-
tation around the C-N bond, and the energetic cost for
this is compensated by favorable interactions between
enzyme and substrate transition state (Harrison andFigure 5. 1H-NMR Spectra of the PP2A-
Derived Peptide
Shown is a region of a one-dimensional NMR
proton spectrum with signals from methyl
groups in the 186LQEVPHEGPMCDL198 pep-
tide in the presence or absence of 5 mM
Ypa1 or the Ypa1-indicated mutants in the
conditions described in the Supplemental
Data.
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421Stein, 1990). Hydrophobic interactions further anchor
the proline in a hydrophobic pocket. The proline bond
is therefore distorted by electrostatic and/or geometri-
cal interactions toward the transition state.
As judged from the Ypa1 peptide complex, no arginine
or any other charged side chain is in an appropriate po-
sition to form a hydrogen bond with the proline peptide
bond. However, a ‘‘conformational distortion mecha-
nism,’’ where catalysis is performed by destabilizing
the substrate by using the binding energy of the peptide
without the need for specific hydrogen bonds, is still
possible. At the present resolution of the structure of
the Ypa1 complex, we are unable to detect a distortion
of the imide bond of the substrate peptide. Recognition
of residues surrounding the substrate proline by electro-
static or hydrogen bonding also undoubtedly contrib-
utes to the efficiency of binding and/or catalysis. The
hypothetical involvement of activated water molecules
in some PPIases leads to more complicated catalytic
mechanisms. The presence of metal ions might also
play a role in the efficiency of catalysis.
Interplay of PP2A Activating and PPIase Activities
In the absence of obvious polar or charged candidate
residues that could play a role in catalysis, we tested
the contribution of hydrophobic residues to binding
and activity. A drastic deletion of the totally conserved
200GVWGLD205 peptide yields a PTPA variant that is in-
active in both the PPIase and the PP2Ai activation reac-
tions (Jordens et al., 2006). This mutation completely
removes the peptide binding site in the a7-a8 loop (Fig-
ure 4B) without affecting the global structure of the pro-
tein in solution (Figure S3). Within this loop, the abso-
lutely conserved Trp202 (colored in green in Figure 1)
certainly makes the most prominent contact by stacking
with the proline (Figure 4C). Consistent with this obser-
vation, the PP2A activation and in vivo activity are se-
verely reduced in Trp202 mutants. The Gly203Phe muta-
tion, which introduces a bulky side chain in the peptide
binding site, has only a mild effect in the PP2Ai activa-
tion reaction, whereas the Asp205Gly and Asp206Gly
mutations in the dimerization site had drastic effects,
and mutations in a distinct conserved patch had no ef-
fect. Surprisingly, only the Asp205 and Asp206 point
mutants, which disrupt the dimerization site, resulted
in a reduction of in vitro PPIase activity. The loss of
in vivo activity despite the persistence of wild-type
PPIase for some mutants could reflect a limitation of
the protease-based PPIase assay, which might be less
sensitive to mutations when measured on short pep-
tides as opposed to longer peptides or the full-length
protein. This can be seen when PPIase is measured by
the 1H-NMR ‘‘peak broadening’’ technique: in this
case, neither the D205G mutant nor the W202G mutant
could isomerase Pro190 in the context of the PP2AC-de-
rived peptide 186LQEVPHEGPMCDL198 as opposed to
wild-type (see Figure 5). Unfortunately, in the prote-
ase-assisted PPIase activity measurements, the chro-
mophore or fluorophore is obligatory positioned next
to the protease cleavage site following the Pro, whereas
the 1H-NMR-based PPIase does not have these limita-
tions although it is only qualitative and not quantitative.
Therefore, although the correlation of PPIase-in vitro
activation and in vivo activity is rather strict, it doesnot exclude the possibility that another function besides
PPIase is necessary for the full activation of PP2A in
vivo. A precedent is found for cyclophilins, whose well-
characterized prolyl isomerase activity is distinct to its
role in inhibition of protein phosphatase 2B (calcineurin)
(Jin and Harrison, 2002).
ATP Binding of PTPA
Both PP2A activating and prolyl isomerase activity
increase significantly in the presence of ATP/Mg2+, al-
though no turnover of the nucleotide is required. No
canonical ATP binding site was identified in the Ypa1
peptide complex, and we did not observe nucleotide
bound to hPTPAD when cocrystallized with either
10 mM ATP/Mg2+ or AMP-PNP/Mg2+. This is consistent
with the very low binding affinity expected for ATP.
Therefore, the activating effect of ATP/Mg2+ could not
be structurally defined. Because the truncated versions
of PTPA, Ypa1, and Ypa2, used in this study for crystal-
lization, can still activate PP2Ai in a reaction that is de-
pendent on MgATP (data not shown), these N- or C-ter-
minal regions are not involved in the binding of the
cofactor. Very recently, it was shown that a conserved
proline in the ATPase domain of the Hsc70 chaperone
assumed alternative conformations in response to ATP
binding and hydrolysis (Vogel et al., 2006), and this
conformational change was important for function.
Although ATP hydrolysis is not observed in the case of
the activation by PTPA, this provides us with a paradigm
for the function of PTPA: the ‘‘proline switch’’ would be in
the PP2A catalytic subunit, and the action of PTPA, with
the ATP cofactor, would be to catalyze the conversion of
PP2Ac from the inactive to the active conformation.
Some authors have assigned a chaperone-like func-
tion to PTPA, required during the synthesis of PP2A
that facilitates incorporation of the required divalent cat-
ions into the phosphatase catalytic site (Fellner et al.,
2003). However, the structural analysis of PTPA is not
consistent with a direct role as a metal-loading protein,
because PTPA lacks obvious metal binding sites. More-
over, incubating human PTPA crystals with a variety of
divalent cations at high concentrations (e.g., 20–50 mM
samarium, zinc, nickel, and manganese) did not reveal
the presence of protein bound metals. Finally proton-in-
duced X-ray emission experiments also failed to demon-
strate the presence of metal ions associated with PTPA
(G.V and D.B., unpublished data). These data suggest
that the ability of PTPA to enhance the correct metal co-
ordination at the catalytic site of PP2A results indirectly
from its capacity to facilitate the correct native confor-
mation of the PP2A catalytic subunit.
In conclusion, the structures of PTPA, Ypa1, Ypa2,
and the Ypa1/peptide complex, combined with previous
and recent functional studies, have allowed a much bet-
ter understanding of the mechanism of action of this
PP2A activator. Cocrystallization with a model peptide
revealed a new class of prolyl isomerases and defines
the molecular basis for recognition of a PP2A substrate.
Structure-based mutational studies demonstrated clear
links between PTPA in vivo activity, PP2A activation of
PTPA, and disruption of the peptide binding and dimer-
ization interface. It has been recognized over the previ-
ous few years that local structural rearrangements in-
duced by peptidyl isomerization can serve as molecular
Molecular Cell
422switches (for review see Andreotti [2003]). Further
insight into this mechanism for PP2Ai activation will re-
quire structure determination of the different conforma-
tional states of the phosphatase.
Experimental Procedures
Cloning, Expression, Purification, and Labeling
Ypa1 truncated at residue 320 and Ypa2 truncated at residue 304
were amplified by PCR using genomic DNA of S. cerevisiae strain
S288C as a template. An additional sequence coding for a 6 histidine
tag was introduced at the 30 end of the gene during amplification.
The PCR product was then cloned into a derivative of pET9 vector.
Expression was done at 15C overnight with the transformed
E. coli Gold (DE3) strain. The His-tagged protein was purified on
a Ni-NTA column (Qiagen Inc.) followed by a gel filtration.
Human PTPA (residues 20–323) was amplified by PCR and cloned
into the NdeI and BamHI sites of a modified version of pET-17b
(Novagen) incorporating an N-terminal His6 tag and an intervening
Prescission protease (Amersham) recognition site. Expression of
PTPA was performed at 16C overnight in Escherichia coli strain
B834 (DE3). PTPA was purified via Talon-affinity chromatography,
PreScission cleavage, and gel filtration. For crystallization, the pro-
tein was eluted in 5 mM HEPES (pH 7.0), 50 mM NaCl, and 3 mM DTT.
Selenomethionine-substituted PTPA and Ypa2 were produced and
purified as the native protein.
Crystallization, Data Collection, Structure Solution,
and Refinement
The crystallization, data collection, structure determination, and
refinement statistics for hPTPAD, Ypa1D, Ypa2D, and the Ypa1D/
peptide complex by X-ray crystallography (Table 1) together with
experimental details are detailed in the Supplemental Data. Only
the radiation damage-induced phasing is described below.
The structure of Ypa2D was solved by SAD aided by radiation
damage-induced phasing using data to 2.80 A˚ resolution. A total
of 315 frames of 1 rotation each was collected on a single crystal.
Overall radiation damage was evidenced by a steady decrease in
average I/s as a function of exposure time. The program HySS
(Grosse-Kunstleve and Adams, 2003) was used to find an initial set
of 20 Se sites based on anomalous differences truncated to 4.0 A˚
resolution. Refinement of the Se atoms and phasing were carried
out with the program SHARP (Bricogne et al., 2003). Initial refine-
ment of the Se sites was carried out against a completely merged
dataset. Additional sites were included in the refinement after in-
spection of residual maps. The final substructure model comprises
23 Se atoms. The data were then split up into three sequential parts,
corresponding, respectively, to merged data from data frames 1–90,
91–180, and 181–315. Separate occupancy factors of the Se atoms
were refined for each of the three datasets. The positional and ther-
mal parameters of each individual Se atom were constrained to
remain identical across all three datasets. The refined values for
most of the Se sites displayed a clear trend of decreasing occupan-
cies across the three sequential datasets—a feature that we
ascribed to site-specific radiation damage. The final phases were
obtained by refining dose-dependent occupancies for the Se atoms
on the scaled but unmerged data (Schiltz et al., 2004). These phases
led to a significantly improved map, which was subjected to density
modification with the program SOLOMON, resulting in a map that
allowed manual building of the model.
Site-Directed Mutagenesis
Point mutants were introduced by using a PCR-based method in
a pET15b-vector (His-tagged Ypa1), a pGEX-vector (GST-tagged
Ypa1), and a pYes2-vector (Yeast transformation). A forward and
reverse mutant primer was used (see Table S1).
PTPA/Ypa Assays as Activator and PPIase
PP2Ai was purified from porcine brain as inactive complex of PP2AD
with PME-1 (Longin et al., 2004). To a 20 ml mixture containing 1.2 to
1.5 U/ml potential PP2A activity and 1 mM ATP, 5 mM MgCl 2 in
20 mM TrisCl, 0.5 mM DTT (pH 7.5) was added 10 ml purified
PTPA/Ypa1 (or mutants) in a serial (5–73) dilution 1:3. After 10 minpreincubation at 30C, 10 ml 32P labeled phosphorylase a with
33 mg/ml protamin and 16 mM ammonium sulfate was added, and
after 10 min at 30C, TCA-soluble 32P was measured (see Van
Hoof et al. [2005] for further details). Two controls were always in-
cluded in duplicate: the maximal PP2A activity measured with a sat-
urating amount of PTPA and MgATP (=100%) and a control without
PTPA/Ypa (subtracted as blanco). One unit PTPA reactivates 30%
PP2Ai in this assay (see Figure S5 for some examples).
The PPIase activity of all mutants was routinely measured by using
the suc-Ala-Ala-Pro-Lys-pNA substrate and the trypsin-assisted
PPIase measurement according to Jordens et al. (2006). kobs values
were measured at 20C [suc-AAPK-pNA] = 8.25 mM; 1 mM ATP,
5 mM MgCl2; [Ypa1] = 0.5 mM; [trypsin] = 4.4 mM. All values are pre-
sented after subtraction of the blanco value, measured with addition
of [BSA] = 0.4 mM (kobs about 0,003 s
21). In some cases, independent
evidence of PPIase activity was sought by the band-shape analysis
technique of the spectra in dynamic proton NMR spectrometry as
described by Hu¨bner et al. (1991) and performed as in Jordens
et al. (2006) with 1 mM peptide (LQEVPHEGPMCDL), 5 mM Ypa1
(or mutant), and 2 mM ATP/10 mM MgCl2 in otherwise the same con-
ditions. For Ypa1, the band broadening is systematically lower than
for the rabbit PTPA (see Figure 4 in Jordens et al. [2006]) for unknown
reasons. Nevertheless, the changes can still be observed for the
wild-type and P268A mutant in comparison with the control (no
Ypa1), whereas this is not the case for the W202G and D205G
mutants (Figure 5). Because this method give only qualitative re-
sults, these are shown in Figure 5 and appreciated in Table 2 with
a Yes or No.
Yeast Transformation and Rapamycin Sensitivity
Figure S6 showing the growth on rapamycin of different mutated
yeast strains and the concerning methods can be found in the Sup-
plemental Data and is appreciated by + and 2 in Table 2.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, six figures, and one table and can be
found with this article online at http://www.molecule.org/cgi/
content/full/23/3/413/DC1/.
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